According to the news of General Technology Group on March 9, general technology China Meheco Group Co.Ltd(600056) (hereinafter referred to as ” China Meheco Group Co.Ltd(600056) “) and Pfizer jointly announced on March 9 that they had signed an agreement on the combined packaging of nevitavir tablets / ritonavir tablets (paxlovid), a covid-19 virus treatment drug China Meheco Group Co.Ltd(600056) will be responsible for the commercial operation of Pfizer Inc COVID-19 virus treatment PAXLOVID in Chinese mainland market during the agreement period. Previously, the State Drug Administration conducted emergency review and approval in accordance with the relevant provisions of the drug administration law and the special drug approval procedures, and conditionally approved the import registration of Pfizer covid-19 virus treatment drug paxlovid.
PAXLOVID is an oral small molecule COVID-19 virus therapy for the treatment of mild to moderate New Coronavirus pneumonia (COVID-19) in adults with severe risk factors, such as elderly, chronic kidney disease, diabetes, cardiovascular disease, and chronic lung disease.
Li Yajun, chairman and assistant general manager of the people’s medical group, said that as the General Secretary of the general Party committee and general manager of the industry, general health. The two sides will rely on their respective resource advantages to fully promote the landing of covid-19 oral therapeutic drugs. “We also hope to take this cooperation as an opportunity to explore multi field and multi angle cooperation with excellent global pharmaceutical companies, so as to jointly protect human health and a better future.”
China Meheco Group Co.Ltd(600056) , a listed company controlled by general technology group (stock abbreviation: China Meheco Group Co.Ltd(600056) , stock code: China Meheco Group Co.Ltd(600056) ), joined General Technology Group in 1999 and has become the only pharmaceutical and medical device asset integration platform under the group China Meheco Group Co.Ltd(600056) has established an industrial pattern led by international trade, supported by the pharmaceutical industry and linked by the pharmaceutical business. The industrial form involves the whole industrial chain of planting and processing, R & D, production, sales, logistics, import and export trade, academic promotion, technical services, focusing on serving the “healthy China” strategy and serving the people’s better life, We are committed to the development of pharmaceutical industry and human health, and strive to build a first-class and international leading pharmaceutical and medical device industry group in China.
